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Summary
Alzheimer’s disease (AD) may result from the accumu-
lation of amyloid-b (Ab) peptides in the brain. The cys-
teine protease cathepsin B (CatB) is associated with
amyloid plaques in AD brains and has been suspected
to increase Ab production. Here, we demonstrate that
CatB actually reduces levels of Ab peptides, especially
the aggregation-prone species Ab1-42, through pro-
teolytic cleavage. Genetic inactivation of CatB in
mice with neuronal expression of familial AD-mutant
human amyloid precursor protein (hAPP) increased
the relative abundance of Ab1-42, worsening plaque
deposition and other AD-related pathologies. Lentivi-
rus-mediated expression of CatB in aged hAPP mice
reduced preexisting amyloid deposits, even thioflavin
S-positive plaques. Under cell-free conditions, CatB
effectively cleaved Ab1-42, generating C-terminally
truncated Ab peptides that are less amyloidogenic.
Thus, CatB likely fulfills antiamyloidogenic and neuro-
protective functions. Insufficient CatB activity might
promote AD; increasing CatB activity could counteract
the neuropathology of this disease.
Introduction
Deposits of amyloid-b (Ab) peptides surrounded by
dystrophic neurites (neuritic plaques) are a pathological
hallmark of AD (Braak and Braak, 1991; Hardy and Sel-
koe, 2002). Although several species of Ab peptides of
39–43 amino acids are produced in the brain (Glenner
and Wong, 1984; Gouras et al., 1998; Masters et al.,
1985), Ab1-42 appears to be particularly critical in AD
pathogenesis. Most mutations associated with autoso-
mal dominant familial AD (FAD) increase the produc-
tion or relative abundance of Ab1-42 (Tanzi and Ber-
tram, 2005). In transgenic mice that overexpress
hAPP and develop age-dependent plaque deposition,
the relative abundance of Ab1-42 correlated with amy-
*Correspondence: lgan@gladstone.ucsf.eduloid deposition and with plaque-independent neuronal
and synaptic deficits (Mucke et al., 2000; Palop et al.,
2003).
In general, Ab levels are determined by the balance
between Ab production and removal, and defects in
the proteolytic degradation of Ab peptides could con-
tribute to AD, especially late-onset sporadic AD (Sel-
koe, 2001). Ab clearance involves several Ab-degrading
enzymes, including insulin-degrading enzyme (IDE), ne-
prilysin (NEP), endothelin-converting enzyme (ECE),
plasmin, matrix metalloproteinase-9 (MMP-9), and indi-
rectly, thimet oligopeptidase (Eckman et al., 2001;
Iwata et al., 2001; Qiu et al., 1998; Tucker et al., 2000;
Yamin et al., 1999; Yan et al., 2006). Chronic transgenic
overexpression of IDE or NEP in AD-related animal
models markedly decreased the levels of Ab1-42 and
Ab1-x, establishing the importance of those enzymes
in regulating Ab turnover in vivo (Leissring et al.,
2003). Lentiviral overexpression of NEP in the brain de-
creased Ab deposits and associated neuropathology in
adult hAPP transgenic mice with significant plaque
loads (Marr et al., 2003). The pronounced reductions
in cerebral Ab levels in APP/presenilin transgenic mice
housed in an enriched environment were associated
with elevated levels of NEP (Lazarov et al., 2005). These
results suggest that the activation of Ab degradation
and clearance is a promising therapeutic approach.
Thus, understanding how levels of Ab, especially Ab1-
42, are regulated by proteolysis has significant im-
plications for both the pathogenesis and the treatment
of AD.
Cathepsin B (CatB) (EC 3.4.22.1), a cysteine protease
of the papain superfamily, degrades peptides and pro-
teins that enter the endolysosomal system by endocyto-
sis or phagocytosis (Chapman et al., 1997). Enzymati-
cally active CatB is secreted through exocytosis
(Linebaugh et al., 1999) and degrades extracellular ma-
trix in pathological conditions, including cancer and
rheumatoid arthritis (Buck et al., 1992; Hashimoto
et al., 2001). In AD brains, neuronal CatB is localized in
most early endosomes, a site of internalization and pro-
cessing of APP to form Ab (Cataldo et al., 1997; Cataldo
and Nixon, 1990). Extracellular CatB is associated with
amyloid plaques (Cataldo et al., 1997; Cataldo and
Nixon, 1990). CatB also colocalizes with both Ab1-40
and Ab1-42 in regulated secretory vesicles in chromaffin
cells (Hook et al., 2005).
Despite the close association of CatB with intracellu-
lar and extracellular Ab, the exact roles of CatB in APP
processing and Ab metabolism in the central nervous
system remain to be defined. It was suspected that
CatB might cleave APP and contribute to Ab generation,
exacerbating neuronal deficits in AD (Cataldo et al.,
1997; Cataldo and Nixon, 1990; Hook et al., 2005;
Mackay et al., 1997). On the other hand, CatB may cata-
lyze the cleavage of Ab peptides, resulting in Ab degra-
dation and neuroprotection. Here we demonstrate that
CatB reduces the relative abundance of Ab1-42 through
limited proteolysis, suggesting that activation of CatB
could offer a therapeutic strategy for AD.
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704Figure 1. Effects of CatB on Plaque Loads
and Neuronal Deficits in hAPP Mice
(A) Western blot analyses of cortical lysates
show comparable levels of FL-hAPP, a-CTF,
b-CTF, and a-sAPP in APP/CatB+/+ and
APP/CatB2/2 mice (n = 9–10/genotype).
Levels of hAPP fragments were normalized
to those of GAPDH. (B) Photomicrographs
of 3D6 immunostaining in the hippocampus
of 6- to 7-month-old hAPP/CatB+/+ and
hAPP/CatB2/2 mice. Scale bar, 400 mm. (C
and D) Genetic ablation of CatB increased
plaque load in hippocampus (n = 10–12/ge-
notype; *p < 0.05, unpaired Student’s t test).
The amount of Ab deposits was calculated
as the percent area of the hippocampus cov-
ered by 3D6-immunoreactive material (C).
Thioflavin S-positive neuritic plaques of the
entire hippocampus region were counted in
seven sections and graphed as average pla-
que number per section (D). (E) APP/CatB2/2
mice have more 3D6-immunoreactive pla-
ques in the cortex than APP/CatB+/+ mice.
Plaques of the entire cortical region were
counted in seven sections and graphed as
average plaque number per section (n = 10–
12/genotype; *p < 0.05, unpaired Student’s
t test). (F) ELISA measurements of hippocam-
pal levels of Ab1-42 and Ab1-x (approximates
total Ab). Ablating CatB increased Ab1-42/
Ab1-x ratios in 6- to 7-month-old mice (n =
10–12 mice/genotype; *p < 0.05, unpaired
Student’s t test). (G) Photomicrographs of
calbindin immunostaining in the hippocam-
pus of 6- to 7-month-old hAPP/CatB+/+
mice, hAPP/CatB2/2 mice, and littermate
controls that do not express human hAPP (CatB+/+ and CatB2/2). Scale bar, 400 mm. (H) Calbindin levels in the dentate gyrus relative to those
in the CA1 regions were significantly lower in hAPP/CatB2/2 mice than in hAPP/CatB+/+ mice and littermate controls (CatB+/+ and CatB2/2) (n =
10–12/genotype; ***p < 0.001, Tukey Kramer post hoc test). Error bars represent means 6 SEM (A, C–F, and H).Results
Genetic Ablation of CatB Increases Plaque
Deposition and Neuropathology in hAPP Mice
To determine the role of CatB in APP processing and Ab
metabolism in vivo, we crossedCatB2/2mice with hAPP
mice that produce high levels of Ab in neurons. CatB
activity was undetectable in CatB2/2 mice and reduced
to 50% of wild-type levels in heterozygotes (CatB+/2)
(Figure S1 in the Supplemental Data available with this
article online). Western blot analyses with an anti-
hAPP antibody (CT-15) revealed that CatB ablation in
hAPP mice did not affect levels of C-terminal fragments
(CTF) of hAPP, including a-CTF, b-CTF, or full-length
hAPP (FL-hAPP) (Figure 1A). Levels of a-sAPP, detected
with 6E10 antibody (Esposito et al., 2004), were not af-
fected by CatB ablation either (Figure 1A). These results
suggest that CatB does not significantly affect the pro-
cessing of hAPP.
Interestingly, hippocampal plaque loads were signifi-
cantly higher in hAPP/CatB2/2 mice than hAPP/CatB+/+
mice at 6 months of age, as shown by immunostaining
with an anti-Ab antibody, 3D6 (Figures 1B and 1C). The
number of neuritic plaques labeled with thioflavin S
was also significantly higher in hippocampi of hAPP/
CatB2/2 mice than in hAPP/CatB+/+ mice (Figure 1D).
In addition, more amyloid deposits were detected inthe cortex of hAPP/CatB2/2 mice than in hAPP/CatB+/+
mice (Figure 1E). These results indicate that CatB is in-
volved in reducing Ab deposition. Using an ELISA assay
for human Ab, we next examined the effects of CatB ab-
lation on hippocampal Ab1-42 and Ab1-x (approximates
total Ab) levels. Although the increase in the absolute
levels of Ab1-42 and Ab1-x in hAPP/CatB2/2 mice did
not reach statistical significance (Figure S2), Ab1-42/
Ab1-x ratios were significantly higher in hAPP/CatB2/2
mice than hAPP/CatB+/+ mice at 6–7 months of age
(Figure 1F). This result is consistent with the increased
plaque deposition in 6- to 7-month-old hAPP/CatB2/2
mice. In 3- to 4-month-old hAPP mice before plaque
deposition, ablation of CatB did not affect the absolute
Ab1-42 or Ab1-x levels or the relative abundance of
Ab1-42 (Figure S2), suggesting that CatB exerts its anti-
amyloidogenic effects during or after the formation of
plaques.
Learning deficits in hAPP mice are influenced by Ab1-
42 levels and, on an inbred C57BL/6 background, corre-
lated strongly with the depletion of the calcium binding
protein calbindin-D28k in granule cells of the dentate
gyrus (Palop et al., 2003, 2005). Consistent with their
increased levels of Ab1-42, 6- to 7-month-old hAPP/
CatB2/2 mice had significantly lower calbindin levels in
the dentate gyrus than age-matched hAPP/CatB+/+
mice (Figures 1G and 1H).
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(A and B) Colocalization of CatB immunoreactivity with amyloid plaques in 16- to 20-month-old hAPP mice. (A) Coimmunostaining of an anti-
CatB antibody (red) with an anti-Ab antibody (3D6, green) (upper panel) or with thioflavin S (green) (lower panel). Yellow signal in the merged
images represents colocalization of CatB with Ab peptides (upper panel) or thioflavin S (lower panel). Scale bars, 100 mm. (B) The area occupied
by fluorescent signals was quantified with ImageJ software (NIH Image). The proportion of plaques immunoreactive for CatB was calculated by
dividing the areas occupied by both CatB and 3D6 or thioflavin S by the area occupied by 3D6 or thioflavin S alone (n = 5; ***p < 0.001, paired
Student’s t test). (C–E) Confocal image shows partial colocalization (yellow) of CatB (red) with dystrophic neurites labeled with 8E5 ([C], green)
and astroglia labeled with anti-GFAP ([D], green) in the hippocampus of 16- to 20-month-old hAPP mice. (E) CatB immunoreactivity (red) was also
partially associated with microglia (green) in 10- to 12-month-old hAPP/CX3CR1+/GFP mice. Scale bars, 50 mm. (F) Confocal image shows coloc-
alization (yellow) of CatB (red) with LAMP1 (green, upper panel) or with EEA1 (green, lower panel) in hippocampal neurons of hAPP mice. Scale
bar, 20 mm.These results suggest that CatB reduces plaque de-
position and relative Ab1-42 levels and protects neurons
against the Ab-induced depletion of synaptic activity-
dependent proteins.
CatB Accumulates Preferentially within Neuritic
Plaques in hAPP Mice
To understand the mechanisms underlying the antiamy-
loidogenic and neuroprotective effects of CatB, we
characterized the association of CatB with amyloid pla-
ques in 16- to 20-month-old hAPP mice. Brain sections
from hAPP mice were colabeled with a CatB-specific
antibody and with either 3D6, which stains both mature
and diffuse Ab deposits, or thioflavin S, which labels
the b sheet structures in mature plaques (Figure 2A).
CatB was present in a subpopulation of 3D6-positive
deposits (Figure 2A) and thioflavin S-positive plaques
(Figure 2A). More thioflavin S-positive than 3D6-positive
deposits were immunoreactive for CatB, indicating that
CatB accumulates preferentially in mature plaques
(Figure 2B). Anti-CatB immunostaining of brain sections
from hAPP/CatB2/2 mice yielded no fluorescent signal
in 3D6-positive plaques or NeuN-positive neurons,
confirming the specificity of CatB antibody (Figure S3).
Notably, in 6- to 7-month-old hAPP/CatB+/+ mice, CatB
was present in most of the amyloid plaques (Figure S4),consistent with the plaque-reducing effect of CatB in
hAPP mice at this age (Figures 1B–1E).
Within neuritic plaques, CatB immunoreactivity over-
lapped with dystrophic neurites labeled with an anti-
hAPP antibody (8E5) (Cheng et al., 2004) (Figure 2C).
These CatB-positive amyloid plaques were also associ-
ated with clusters of reactive astroglia labeled with
GFAP antibody (Figure 2D), as well as microglia, as
shown by crossing hAPP mice with CX3CR1+/GFP mice,
in which microglia are labeled with GFP (Figure 2E).
Interestingly, CatB activity was present in the superna-
tants of primary cultures enriched for neurons, astro-
cytes, or microglia; the highest levels were detected in
microglial cultures (Figure S5). These results suggest
that extracellular CatB accumulating within neuritic pla-
ques could be produced by all three cell types, including
activated microglia surrounding the plaques.
CatB in hippocampal CA1 pyramidal neurons of hAPP
mice colocalized with lysosomal membrane glycopro-
tein 1 (LAMP1), a lysosomal marker (Figure 2F). CatB
also colocalized with endosome-associated autoanti-
gen 1 (EEA-1)-positive early endosomes, a site involved
in APP processing and Ab generation (Figure 2F). The
accumulation of CatB in early endosomes in neurons
of vulnerable regions of hAPP brains is consistent with
a role of neuronal CatB in modulating Ab levels.
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706Figure 3. CatB Reduces Ab Levels in Primary
Neurons
Levels of human Ab1-x and Ab1-42 in the
supernatants were determined with an Ab
ELISA and normalized to the protein concen-
trations in the cell lysates. Error bars repre-
sent means 6 SEM (A–B and D–I). n refers
to number of samples per condition. (A and
B) Levels of Ab1-42 (A) and Ab1-x (B) in
CatB2/2 (n = 6) andCatB+/+ neurons (n = 8) in-
fected with hAPP adenovirus. *p < 0.05,
Mann-Whitney U test. (C–F) Inhibition of
CatB increased Ab levels in hAPP primary
neurons. Diagram (not to scale) of the lentivi-
ral vector Lenti-shCatB, which expresses
both EGFP and shCatB (C). CatB activities
(D) were significantly lower in hAPP neurons
infected with Lenti-shCatB than in those in-
fected with the control lentiviral vector ex-
pressing scrambled shRNA (Lenti-shSCR)
(n = 15; ***p < 0.001, unpaired Student’s t
test). Levels of Ab1-42 (E) and Ab1-x (F)
were significantly higher in cultures infected
with Lenti-shCatB than in those infected
with Lenti-shSCR (n = 15; *p < 0.05, unpaired
Student’s t test). Average Ab levels in Lenti-
shSCR-infected cultures were arbitrarily set
as 1. (G–I) Overexpression of CatB decreased
Ab levels in hAPP primary neurons. CatB ac-
tivities (G) were significantly increased in
hAPP neurons infected with Lenti-CatB
(n = 4, ***p < 0.001, unpaired Student’s t
test). Levels of Ab1-42 (H) and Ab1-x (I) were
significantly lower in cultures infected with
Lenti-CatB than in those infected with equal
amounts of Lenti-control (n = 4; *p < 0.05, un-
paired Student’s t test). Average Ab levels in
Lenti-control-infected cultures were arbi-
trarily set as 1.CatB Reduces Ab Levels in Primary Neurons
To investigate whether CatB directly affects Ab levels in
neurons, we transduced primary cortical neurons from
CatB2/2 mice and CatB+/+ littermate controls with an
adenoviral vector expressing hAPP. Ab1-42 levels
were significantly higher in the supernatants from
CatB2/2 neurons than CatB+/+ neurons (Figure 3A).
Lack of CatB did not increase Ab1-x levels in these cul-
tures significantly (Figure 3B).
In complementary experiments, we inhibited CatB ex-
pression in primary cortical neuronal cultures from hAPP
mice with a lentiviral vector encoding a small hairpin
RNA targeting CatB (Lenti-shCatB) (Figure 3C). CatB
activity was significantly lower in cultures expressing
Lenti-shCatB than in cultures expressing a scrambled
shRNA (Lenti-shSCR) (Figure 3D). Inhibiting CatB signif-
icantly increased Ab1-42 levels, suggesting that CatB
negatively regulates Ab1-42 levels (Figure 3E). Ab1-x
levels were also significantly elevated in cultures in-
fected with Lenti-shCatB, indicating that CatB also
reduces total Ab levels (Figure 3F).
To further confirm the effects of CatB on Ab levels, we
increased CatB activity in primary neuronal culturesfrom hAPP mice with a lentiviral vector encoding mouse
CatB cDNA (Lenti-CatB). Infection with Lenti-CatB re-
sulted in significant increase in CatB activity
(Figure 3G). Both Ab1-42 and Ab1-x levels were
significantly reduced in cultures overexpressing CatB
(Figures 3H and 3I).
CatB Is Increased in Ab1-42-Treated Neuronal Cells
and in Brains of hAPP Mice
Our results so far demonstrate that levels of Ab, includ-
ing Ab1-42, are downregulated by CatB in hAPP mice
and primary neuronal cultures. Notably, elevated levels
of Ab1-42 stimulate microglia to express more CatB
mRNA (Gan et al., 2004). To determine if Ab1-42 also reg-
ulates CatB in neuronal cells, where the majority of Ab is
made, we stimulated neuroblastoma (N2A) cells with
increasing amounts of Ab1-42 and Ab1-40. Both CatB
mRNA levels (Figure 4A) and enzymatic activities
(Figure 4B) were markedly increased by Ab1-42; Ab1-
40 had little or no effect. Treatment with preaggregated
Ab1-40, however, induced a modest but significant
increase in CatB activity, supporting the notion that
Cathepsin B Reduces Plaques by Cleaving Ab Peptide
707Figure 4. Upregulation of CatB by Ab1-42 in
N2A Cells and in Young and Middle-Aged
hAPP Mice
(A–C) N2A cells were treated with increasing
amounts of nonaggregated Ab1-42 or Ab1-
40 for 24 hr and harvested for quantitative
RT-PCR and CatB activity assays. NT, non-
treated. CatB mRNA levels (A) and CatB en-
zymatic activities (B) were significantly ele-
vated by 20 mM Ab1-42; Ab1-40 had little
effect. (C) Preaggregated Ab1-40 (20 mM)
had a modest but significant effect. Error
bars represent means 6 SEM (n = 4–6 sam-
ples/condition; **p < 0.01; ***p < 0.001; *p <
0.05, Tukey Kramer post hoc test).
(D) CatB activity levels were significantly
higher in young (1–3 months) and middle-
aged (7–8 months), but not elderly (16–20
months), hAPP mice, than in age-matched
nontransgenic (ntg) controls. Error bars rep-
resent means 6 SEM (n = 8–18 mice/geno-
type; *p < 0.05; **p < 0.01, Tukey Kramer
post hoc test).regulation of CatB is influenced by the assembly states
of Ab peptides (Figure 4C).
To determine if Ab levels modulate CatB activities
in vivo, we compared the enzymatic activities of CatB
in the hippocampus of hAPP mice. Compared with
age-matched nontransgenic controls, CatB levels were
higher in hAPP mice both before (1–3 months) and after
(7–8 months) plaque deposition (Figure 4D), suggesting
that the hAPP/Ab-induced increase in CatB activities
does not depend on insoluble Ab deposits in vivo. At
16–20 months, CatB activities were similar to those in
nontransgenic controls, indicating that hAPP/ Ab failed
to stimulate CatB at old age (Figure 4D).
CatB Mediates C-Terminal Truncations
of Ab1-42 In Vitro
Since the relative abundance of Ab1-42 was increased in
the hippocampus of hAPP/CatB2/2mice and inCatB2/2
neurons overexpressing hAPP, we hypothesized that
Ab1-42 is a substrate for CatB and that CatB reduces
levels of Ab1-42 through proteolytic cleavage. Under
cell-free conditions, synthetic Ab1-42 was incubated
with purified CatB at pH 6.0, a pH close to that of endo-
somes, where CatB is likely to encounter Ab intracellu-
larly (Cataldo et al., 1997; Hook et al., 2002) (Figure 1F).
The proteolytic products were analyzed with SELDI-
TOF mass spectrometry. Incubating Ab1-42 with CatB
resulted in the dose-dependent generation of Ab1-40,
Ab1-38, and Ab1-33 through proteolytic cleavage at
Val40-Ile41, Gly38-Gly39, and Gly33-Leu34 (Figure 5A). No
truncations occurred in the presence of the inhibitor
CA074 or in the absence of CatB, confirming that the
truncations were dependent on the proteolytic activity
of CatB. Increasing the concentration of CatB de-
creased Ab1-42 and increased Ab1-38 (Figures 5A).
The dose-dependent cleavage of Ab1-42 was confirmedby western blot analysis of acid-urea gels (Figure 5B).
Levels of Ab1-40 were increased initially at lower doses
(100–400 ng/ml), but decreased at higher doses (0.4–2.5
mg/ml) (Figure 5A). These results indicate that CatB acts
as a carboxydipeptidase that cleaves Ab1-42 at the C
terminus to generate Ab1-40, which in turn serves as
a substrate for the generation of Ab1-38.
Although CatB did not appear to completely degrade
Ab peptides, Ab1-33 was also generated (Figures 5A and
5D) in a dose-dependent manner, presumably by endo-
peptidase activity. Consistent with the weaker endo-
peptidase than carboxydipeptidase activity of CatB at
acidic pH (4.0–6.0) (Musil et al., 1991; Nagler et al.,
1997), higher concentrations of CatB were required to
generate Ab1-33 than to generate Ab1-40 and Ab1-38
(Figure 5A). Interestingly, even when Ab1-40 was almost
completely converted to Ab1-38, no Ab1-36 was gener-
ated from Ab1-38 (Figure S6), indicating that Ab1-38 is
not a substrate for CatB’s carboxydipeptidic activity.
Thus, CatB may counteract amyloidosis by catalyzing
the sequence-specific C-terminal truncation of Ab1-42.
CatB Cleaves Aggregated Ab1-42 and Reduces
Levels of Ab Fibrils In Vitro
Next, we investigated whether CatB also cleaves soluble
and insoluble Ab1-42 assemblies. The assembly state of
Ab1-42 was confirmed with negative-staining electron
microscopy (Figure 5C). Nonfibrillar Ab1-42 assemblies
were highly toxic in cultured primary neurons (Chen
et al., 2005; Hartley et al., 1999) and, at pH 6.0, were
cleaved by CatB as efficiently as nonaggregated prepa-
rations, resulting in the same C-terminally truncated
peptides, Ab1-40, Ab1-38, and Ab1-33 (Figure 5D), which
are less toxic and fibrillogenic than Ab1-42 (Iijima et al.,
2004; Zhang et al., 2002). Incubation of CatB induced
a marked decrease in the amounts of high-molecular
Neuron
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CatB-specific activity was abolished by its inhibitor (CA074). Similar results were obtained in two to five independent Ab preparations. (A) Seldi-
TOF mass spectrometry analysis of dose-dependent cleavage of fresh Ab1-42 (nonaggregated) by pure CatB (100–2500 ng/ml) at pH 6.0. (B) A
western blot of an acid-urea gel shows dose-dependent generation of Ab1-40 and Ab1-38 from Ab1-42. Uncleaved Ab1-42 and Ab1-40 peptides
served as MW controls. (C) Photomicrograph of fresh Ab and nonfibrillar and fibrillar Ab assemblies visualized with negative-staining electron
microscopy. Scale bar, 200 nm. (D and F) Seldi-TOF mass spectrometry analysis of CatB-induced cleavage of aggregated Ab1-42 (nonfibrillar
and fibrillar). Nonfibrillar Ab1-42 assemblies were cleaved as efficiently as fresh Ab1-42 at pH 6.0 (D). CatB induced cleavage of fresh Ab and
nonfibrillar and fibrillar Ab assemblies at pH 7.0 (F). (E) A western blot of Tricine gel (16%) shows effects of CatB (1–2 mg/ml) on Ab1-42 assem-
blies, including high MW Ab oligomers, and putative monomeric, dimeric, trimeric, and tetrameric Ab1-42 (arrows), in the presence or absence of
CA074, according to the MW markers (3.5–75 kDa). (G) Electron microscopy photomicrograph of preformed Ab1-42 fibrils incubated with CatB in
the presence or absence of its inhibitor CA074. Scale bar, 200 nm.weight (MW) Ab assemblies, as shown on Tricine SDS-
PAGE gels. Levels of low-MW Ab1-42 oligomers and
monomers, detected with an antibody specific for Ab1-
42, were also reduced. Inclusion of the CatB inhibitor
CA074 significantly diminished such effects (Figure 5E).
These results suggest that CatB effectively targets Ab
assemblies in vitro.
At neutral pH (w7.0), the ability of CatB to cleave Ab,
especially nonaggregated (fresh) Ab, was markedly re-
duced (Figure 5F). Nevertheless, nonfibrillar and fibrillar
Ab assemblies were cleaved by CatB even at neutral pH,
resulting in the same truncated Ab species observed at
pH 6.0 (Figures 5A and 5F). The ability of CatB to cleaveeven aggregated Ab1-42 suggested that CatB might be
able to reduce preformed Ab fibrils. Indeed, incubation
of fibrillar Ab1-42 with CatB did reduce the amount of
fibrillar structures (Figure 5G). This effect depended on
the proteolytic activity of CatB, as demonstrated by inhi-
bition with CA074 (Figure 5G).
CatB Gene Transfer Reduces Amyloid Plaques
in Aged hAPP Mice
The ability of CatB to cleave Ab1-42 aggregates and the
accumulation of CatB within amyloid plaques support
the notion that CatB might reduce established plaques
in aged hAPP mice. To test this hypothesis, we injected
Cathepsin B Reduces Plaques by Cleaving Ab Peptide
709Figure 6. CatB Gene Transfer Reduces Amyloid Plaques in Aged hAPP Mice
All stereotaxic injections were performed on the left side; the uninjected right side served as an internal control. Scale bars, 400 mm (A, C, and E).
(A) Representative CatB immunostaining of the Lenti-CatB-injected (left) and uninjected (right) hippocampus in a 12- to 15-month-old hAPP
mouse. (B) CatB enzymatic activities in hippocampi of CatB+/2 mice after injection of Lenti-CatB or Lenti-Control (n = 3 mice/group; *p <
0.05, unpaired Student’s t test). (C) Representative 3D6 immunostaining of the Lenti-CatB-injected (left) and uninjected (right) hippocampus
in a 12- to 15-month-old hAPP mouse. (D) Reduction of 3D6-immunoreactive Ab deposits in the hippocampus of 12- to 15-month-old hAPP
mice after injection of Lenti-CatB (10 mice) or Lenti-NEP (7 mice), but not Lenti-Control (5 mice). For each mouse, the extent of hippocampal
Ab deposits was expressed as the ratio between the percent area occupied by 3D6 immunoreactivity on the injected versus uninjected side.
*p < 0.05, Tukey Kramer post hoc test. (E) Representative photomicrograph of thioflavin S staining of the Lenti-CatB-injected (left) and uninjected
(right) hippocampus in a 12- to 15-month-old hAPP mouse. (F) Reduction of thioflavin S-positive plaques in the hippocampus of 12- to 15-month-
old hAPP mice after injection of Lenti-CatB (10 mice), but not Lenti-NEP (7 mice) or Lenti-Control (5 mice). For each mouse, the extent of hippo-
campal plaques was expressed as the ratio of the percent area of thioflavin S-positive plaques on the injected versus uninjected side. *p < 0.05,
Tukey Kramer post hoc test.Lenti-CatB, the vector we used to increase CatB levels in
primary neuronal cultures (Figure 3G), into the hippo-
campus of 12- to 15-month-old hAPP mice, which
have significant plaque deposition. Lenti-control, which
does not encode a functional protein, served as a nega-
tive control for nonspecific viral effects. A lentiviral vec-
tor overexpressing NEP (Lenti-NEP) (Marr et al., 2003)
served as a positive control. Three weeks after the ste-
reotaxic injections, CatB immunoreactivity (Figure 6A)
and enzymatic activity (Figure 6B) were much stronger
in the injected hippocampus, especially in the dentate
gyrus, than those in the contralateral side. Lenti-NEP
also induced higher NEP immunoreactivity in the den-
tate gyrus (data not shown).
Injection of Lenti-CatB (Figure 6C) or Lenti-NEP signif-
icantly reduced 3D6-postive Ab deposits in the ipsilat-
eral dentate gyrus; control virus had no effect (Figure
6D). These results suggest that, in aged hAPP mice,
CatB reduces preexisting plaque load as effectively asNEP. Notably, CatB gene transfer markedly reduced
thioflavin S-positive neuritic plaques (Figures 6E and
6F), whereas Lenti-NEP did not (Figure 6F). Thus, CatB
was more effective than NEP in removing aggregated
Ab in mature amyloid plaques.
Discussion
Our study demonstrates that CatB exerts antiamyloido-
genic and neuroprotective effects in vivo, most likely
through C-terminal proteolytic truncation of Ab1-42.
CatB has been implicated in AD because of its promi-
nent association with neuritic plaques and enlarged en-
dosomes in AD brains (Cataldo et al., 1997, 2004; Cata-
ldo and Nixon, 1990; Hook et al., 2005; Mackay et al.,
1997). However, these studies postulated that CatB
might contribute to Ab generation through proteolysis
of APP. We directly tested this hypothesis and
discovered that CatB ablation had no effect on APP
Neuron
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and plaque deposition. Moreover, CatB cleaved fibrillar
as well as nonfibrillar assemblies of Ab1-42 into shorter
Ab peptides that are less pathogenic and amyloido-
genic. Thus, this function of CatB should counteract
both plaque-dependent and plaque-independent neu-
ronal deficits.
Consistent with this notion, reducing CatB activity in
hAPP mice augmented the neuritic plaque burden and
depleted neuronal calbindin levels in the dentate gyrus.
Calbindin reductions in the dentate gyrus of hAPP mice
correlate tightly with Ab-dependent deficits in learning
and memory (Palop et al., 2003). While hAPP/Ab expres-
sion was sufficient to deplete calbindin in the dentate
gyrus of inbred C57BL/6 mice (Chin et al., 2005; Palop
et al., 2003, 2005), CatB ablation was required to elicit
this molecular alteration in the hAPP mice analyzed
here, which were on a C57BL/6 3 129 hybrid back-
ground. The relative resistance to calbindin depletion
in hAPP mice on a hybrid background likely reflects het-
erosis, or hybrid vigor, a well-documented phenomenon
in plants and mammals (Comings and MacMurray, 2000).
Interestingly, the proteolytic activities of CatB were
stimulated by high levels of Ab1-42 in young and mid-
dle-aged, but not old, hAPP mice. Thus, upregulation
of CatB may represent a protective mechanism that fails
with aging. Aging also reduces the levels of somato-
statin, resulting in markedly decreased NEP levels in vul-
nerable regions of the aging brain (Iwata et al., 2004;
Saito et al., 2005). Together, these studies provide evi-
dence that aging-dependent defects in Ab catabolism
by proteolysis may underlie Ab accumulation in late-on-
set sporadic AD.
Within the lysosomal cysteine protease family, CatB
possesses the unique ability to act both as a dipeptidyl
carboxypeptidase and an endopeptidase. Because it
has two histidine residues (His110 and His111) in a 20
residue occluding loop on the primer side of its catalytic
site, CatB has greater carboxydipeptidic than endopep-
tidic activity (Illy et al., 1997; Khouri et al., 1991; Nagler
et al., 1997). Both proteolytic activities appear to be in-
volved in the CatB-dependent C-terminal truncation of
Ab1-42. Dipeptidyl carboxypeptidase activity would be
expected to lead to sequential conversion of Ab1-42
into Ab1-40 and Ab1-38, whereas Ab1-33 appears to
be the only fragment generated through endopeptidic
cleavage.
The generation of distinct C-terminally truncated Ab
fragments by CatB offers a unique mechanism to mod-
ulate the levels of Ab, especially Ab1-42. Interestingly,
CatB also catalyzes C-terminal truncations of epidermal
growth factor and insulin-like growth factor, leading to
the negative regulation of their signaling (Authier et al.,
1999; Tsujinaka et al., 1995). Since Ab oligomers have
been shown to inhibit neurotransmission and synaptic
plasticity (Cleary et al., 2005; Walsh et al., 2002; Walsh
and Selkoe, 2004), CatB might affect the activity in neu-
ronal circuits by modulating the levels of different Ab
assemblies. Thus, CatB may fulfill important regulatory
functions through limited proteolysis under both physi-
ological and pathophysiological conditions.
The mechanisms that underlie CatB’s cleavage of ag-
gregated Ab preparations are not well understood. Few
enzymes efficiently degrade highly aggregated Ab pep-tides. Naturally occurring Ab dimers and trimers are re-
sistant to IDE in the culture medium, suggesting that
IDE cannot effectively degrade oligomeric Ab (Qiu
et al., 1998; Vekrellis et al., 2000). Although NEP is capa-
ble of degrading oligomeric Ab peptides (Kanemitsu
et al., 2003; Huang et al., 2006), we were unable to find ev-
idence in the literature that it efficiently degrades proto-
fibrillar and fibrillar Ab. Plasmin degrades fibrillar Abwith
a proteolytic efficiency that is only about 1% of that for
freshly dissolved (i.e., largely monomeric) Ab (Tucker
et al., 2000). Recently, MMP-9 was found to degrade
Ab fibrils in vitro (Yan et al., 2006). It is likely that IDE,
NEP, plasmin, MMP-9, and CatB target different forms
of Ab, collaborating to effectively remove Ab and prevent
AD. In primary neurons from hAPP mice, CatB reduces
levels of both Ab1-42 and total Ab, suggesting that
CatB could facilitate complete degradation of Ab pep-
tides by generating C-terminally truncated Ab peptides
that are less prone to aggregation and thus are degraded
more easily by other proteases, such as NEP and IDE.
Ablation of CatB increased the relative abundance of
Ab1-42 in purified primary neuronal cultures containing
<5% of glia but not in 3- to 4-month-old mice. Conceiv-
ably, alternative Ab-degrading activities of astrocytes
and microglia (Wyss-Coray et al., 2001; Koistinaho
et al., 2004) may have compensated for the lack of CatB
in vivo. However, CatB exerted robust antiamyloidogenic
effects in 6- to 7-month-old mice, suggesting a predomi-
nant effect on Ab during or after plaque formation. Our
finding that CatB gene transfer effectively cleared pre-
formed plaques in 12- to 15-month-old hAPP mice further
supports this conclusion. Indeed, CatB was more effec-
tive than NEP in reducing thioflavin S-positive neuritic
plaques, likely due to CatB’s ability to target aggregated
Ab and its accumulation within neuritic plaques. These
results reinforce the notion that CatB and NEP contribute
to overall Ab degradation in the brain by targeting differ-
ent forms of Ab, reflecting their distinct proteolytic prop-
erties and subcellular localizations.
Accumulating evidence supports the notion that Ab
oligomers, but not Ab plaques, are critical in mediating
synaptic and cognitive deficits in hAPP mice (Cleary
et al., 2005; Hsia et al., 1999; Lesne et al., 2006; Mucke
et al., 2000; Walsh et al., 2002). Although CatB efficiently
reduces oligomeric Ab1-42 in vitro, it is not yet known
whether the overexpression of CatB also reduces levels
of toxic Ab oligomers in vivo. CatB could directly reduce
the local concentration of Ab1-42 oligomers through
proteolytic cleavage of monomers and oligomers. On
the other hand, the cleavage of highly fibrillogenic
Ab1-42 could facilitate dissociation of fibrils, resulting
in an increase in the local oligomer concentration, and
thus be harmful. Further studies are required to deter-
mine the effects of CatB overexpression on Ab oligo-
mers and associated neuronal deficits in hAPP mice.
CatB has the potential to act intracellularly and extra-
cellularly, as well as in diverse cell types. Therefore, it
could help remove Ab from the extracellular milieu or
attenuate intracellular Ab toxicity, which has been asso-
ciated with the accumulation of Ab1-42 aggregates in
endosomal vesicles and other cellular organelles (Espo-
sito et al., 2004; Oddo et al., 2006; Takahashi et al., 2004;
Zhang et al., 2002). In support of this notion, coinfusion
of Ab with a cysteine protease inhibitor increased
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mulation of Ab1-42 in rat brain (Frautschy et al., 1998).
Since microglia express higher levels of CatB than other
cell types, CatB might also promote microglia-mediated
Ab clearance by cleaving Ab aggregates internalized
through phagocytosis.
Independent of the specific sites in which CatB
launches its most critical attack on Ab1-42, our findings
suggest that inhibition or loss of CatB activity could
interfere with its protective function and promote the
development of AD, whereas increasing CatB activity
could counteract Ab accumulation and aggregation, of-
fering a potential approach to the treatment of AD.
Experimental Procedures
Mice
CatB2/2 mice (129sv) obtained from Dr. Hidde Ploegh (Harvard
Medical School, Boston, MA) (Deussing et al., 1998) were crossed
with hAPP mice (C57BL/6J) from line J20 (Mucke et al., 2000). The
first cross resulted in hAPP/CatB+/2 mice, which were crossed
with CatB+/2 (CatB heterozygotes that do not express hAPP) to gen-
erate six genotypes: hAPP/CatB2/2, hAPP/CatB+/+, hAPP/CatB+/2,
CatB2/2, CatB+/+, and CatB+/2. PCR-based genotyping was per-
formed as described (Deussing et al., 1998; Mucke et al., 2000).
We have also generated hAPP/CX3CR1+/GFP mice, which express
green fluorescent protein (GFP) in microglia that retain normal frac-
talkine receptor function (Jung et al., 2000) by crossing hAPP mice
with CX3CR12/2 mice with targeted GFP insertion (Dr. D Littman,
New York University School of Medicine, New York, NY). All mea-
surements were performed on gender-balanced groups. Anesthe-
tized mice were flush perfused transcardially with PBS. One hemi-
brain was fixed in 4% phosphate-buffered paraformaldehyde at
4C for 48 hr, and the other was stored at 270C. All experiments
were approved by the Committee on Animal Research of the Univer-
sity of California, San Francisco (UCSF).
Immunohistochemistry and Quantitation
of Immunoreactive Structures
Sliding microtome sections (30 mm) were prepared for immunohisto-
chemistry. For fluorescence double-labeling, sections were incu-
bated first with rabbit anti-CatB (1:1000, Upstate Biotechnology,
Lake Placid, NY), mouse anti-EEA1 (1:50, BD Biosciences, Franklin
Lakes, NJ), mouse mAb anti-Ab (1:500, 3D6, Elan Pharmaceuticals,
South San Francisco, CA), mouse anti-APP (8E5, 1:1000, Elan Phar-
maceuticals), anti-NeuN (1:1000 Chemicon, Temecula, CA), or rabbit
anti-GFAP (1:1000, Sigma, St. Louis, MO), and then with fluorescein-
labeled donkey anti-rabbit (1:300, Jackson ImmunoResearch, West
Grove, PA) and Texas red-labeled donkey anti-mouse (1:300, Jack-
son ImmunoResearch). Microglia were labeled with GFP in the het-
erozygous CX3CR1+/GFP mice (Jung et al., 2000) that express or do
not express hAPP. Amyloid plaques were stained with thioflavin S.
High-power immunofluorescence images were obtained by confocal
microscopy (Radiance 2000, BioRad, Hercules, CA). Lower-power
digitized images were acquired with a BX-60 microscope (Olympus,
Melville, NY) and Axiovision software (Carl Zeiss, Germany). Areas of
fluorescent signal were quantified with ImageJ software (NIH Image).
The proportion of CatB-immunoreactive plaques was calculated by
dividing the areas occupied by both CatB and either 3D6 or thioflavin
S by the area occupied by 3D6 or thioflavin S alone.
Calbindin expression in the dentate gyrus and plaque loads in the
hippocampus were quantified as described (Palop et al., 2003). After
endogenous peroxidase activity was quenched, sections were incu-
bated with rabbit anti-calbindin (1:15,000, Swant, Bellinzona, Swit-
zerland), biotinylated goat anti-rabbit (1:200, Vector Laboratories,
Burlingame, CA), or biotinylated mouse monoclonal antibody 3D6
(5 mg/ml, Elan). Binding of the antibody was detected with the Elite
kit (Vector Laboratories) using diaminobenzidine and H2O2 for devel-
opment. Images were obtained with a DEI-470 digital camera (Op-
tronics, Goleta, CA). The integrated optical density from three coro-
nal sections was determined with a Bioquant image analysis system
and averaged in two areas of the molecular layer of the dentate gyrusand of the stratum radiatum of the CA-1 region, in which calbindin
levels remained stable. Calbindin levels were expressed as the ratio
of integrated optical density in the molecular layer and in the stratum
radiatum of the CA1. The plaque load was calculated as the percent
area of the hippocampus covered by 3D6-immunoreactive material.
Three coronal sections were analyzed per mouse, and the average of
the individual measurements was used to calculate group means.
Cell Culture and Lentiviral/Adenoviral Infection
Unless otherwise noted, all cell culture supplies, medium, and anti-
biotics were from Invitrogen (Carlsbad, CA). The murine neuronal
cell line N2A was maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin G, and 100mg/ml streptomycin at 37C in a humid-
ified atmosphere containing 5% CO2. Before treatment, the medium
was replaced with Neurobasal A medium supplemented with N2,
and the cells were treated with fresh Ab1-42 or Ab1-40 at various
concentrations for 24 hr.
For primary neuronal cultures, cortices from mouse pups of differ-
ent genotypes were isolated on postnatal day 0 or 1. Dissociated
cells were plated at 800,000 cells/ml in Neurobasal A medium sup-
plemented with B27, 100 U/ml penicillin G, and 100 mg/ml streptomy-
cin. The genotypes of individual cultures were determined by PCR
analysis of the tails of the pups from which the cells were obtained.
Expression of CatB in APP-FAD neurons (hAPP) was inhibited by
overexpressing shRNA, which targets endogenous mouse CatB
under the U6 promoter. The target sequence was 50-GAAGCTGTG
TGGCACTGTC-30. The U6-shRNA expression cassette (pSilencer
1.0, Ambion, Austin, TX) was inserted between the PacI and the
NheI sites of a modified FUGW (Dr. David Baltimore, California Insti-
tute of Technology, Pasadena, CA, and Dr. Pavel Osten, Max-Planck
Institute, Heidelberg, Germany) to generate Lenti-shCatB. A con-
struct expressing a scrambled shRNA was used as a control
(Lenti-shSCR). To overexpress CatB, the EGFP expression cassette
in FUGW was replaced with mouse CatB cDNA (MGC-6211, ATCC,
Manassas, VA) or nothing to generate Lenti-CatB or Lenti-control.
Lentiviral vectors were generated, purified, and titered as described
(Chen et al., 2005). Briefly, recombinant lentivirus was generated by
cotransfecting the transfer vector with two helper plasmids, delta8.9
(packaging vector) and VSV-G (envelope vector), into 293T cells
(American Type Culture Collection) and purified by ultracentrifuga-
tion. Viral titers were determined by p24 ELISA (Perkin Elmer, Bos-
ton, MA) at the UCSF Laboratory of Clinical Virology. After 5 days
in culture, cortical neuronal cultures from hAPP pups were infected
with Lenti-shCatB to inhibit CatB activity or with Lenti-CatB to ele-
vate CatB activity. Equal amounts of Lenti-shSCR and Lenti-control
were used as controls for Lenti-shCatB and Lenti-CatB, respec-
tively. Four days later, supernatants were collected for Ab1-x and
Ab1-42 ELISA (Johnson-Wood et al., 1997), and cell lysates were
harvested for assays of CatB activity (EMD Biosciences, San Diego,
CA) and protein levels (BCA, Pierce Biotechnology, Rockford, IL).
To overexpress hAPP, an adenoviral vector encoding human
APP695 cDNA under control of the cytomegalovirus promoter was
used to infect neurons cultured fromCatB+/+ andCatB2/2 pups after
5 days in culture. The neurons were initially cultured in B27 and
switched to N2 medium by half change on days 2, 3, and 4. On
day 7, supernatants and cells were harvested for Ab ELISA, CatB
activity assay, and BCA protein assays.
Stereotaxic Injection of Lentiviral Vectors
The recombinant lentiviral vectors (3 ml, an equivalent of p24w150–
200 ng of lentiviral particles) were stereotaxically injected into the
hippocampus of hAPP mice at the following coordinates: anterior
posterior,22.2; medial lateral,61.8, dorsal ventral,21.9. To confirm
region-specific overexpression of CatB and NEP in hAPP mice, 3
weeks after injection, mice were flush perfused transcardially with
saline, and brain tissues were rapidly removed. Both hemibrains
were postfixed in 4% paraformaldehyde for immunostaining. The
contralateral side was marked with a notch before sectioning. The
transduction of enzymatically active CatB was confirmed in a cohort
ofCatB+/2mice 3 weeks after the injection. The hippocampal lysates
were prepared by homogenizing in Cytobuster (Innozyme Cathepsin
B Activity Assay Kit, EMD Biosciences) in the absence of protease
Neuron
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pared with that of the contralateral side.
The injection-induced effects on Ab deposition were expressed as
the ratio of the percent area of 3D6-immunoreactive or thioflavin
S-positive material on the injected versus the noninjected side.
Quantitative analyses were performed with ImageJ software (NIH
Image). Three to five coronal sections were analyzed per mouse,
and the average ratios were used to calculate group means.
Quantification of Ab
Snap-frozen hippocampi were homogenized in guanidine buffer,
and human Ab peptides were quantitated by ELISA as described
(Johnson-Wood et al., 1997). Human Ab in the supernatants of pri-
mary cortical neurons was also measured by ELISA. The Ab1-42
ELISA detects only Ab1-42, and the Ab1-x ELISA detects Ab1-40,
Ab1-42, and Ab1-43, as well as C-terminally truncated forms of Ab
containing amino acids 1–28.
Ab Preparations and Electron Microscopy
Ab1-42 and Ab1-40 were from rPeptide (Athens, GA). Ab powders
lyophilized with hexafluoroisopropanol were reconstituted in dry
dimethylsulfoxide (Sigma) at a concentration of 5 mM. Aggregated
Ab1-42 was prepared based on protocols developed in previous
studies (Dahlgren et al., 2002; Lambert et al., 1998). For nonfibrillar
Ab assemblies, DMEM/F-12 was added to achieve a final peptide
concentration of 100 mM and incubated at 4C for 24 hr. For
fibrillar conditions, 10 mM HCl was added to achieve a final peptide
concentration of 100 mM and incubated for 24 hr at 37C. For nonag-
gregated conditions (fresh Ab), the 5 mM Ab in Me2SO4 was diluted
directly into cell culture medium. For Ab1-40 aggregation, Ab1-40
was reconstituted in H2O at a concentration of 5 mg/ml and incu-
bated for 1 week at 37C.
Ab1-42 and Ab1-40 samples were characterized by negative-
staining electron microscopy (JEOL 1230, Peabody, MA). Samples
were prepared with ‘‘matured’’ carbon-coated grids and 2% potas-
sium phosphotungstate (pH 6.5), using the drop method (Hamilton
et al., 1980), and examined at 80 KV with a condenser aperture
of 200 mm and an objective aperture of 50 mm. Images were
obtained with a Gatan Ultrascan USC1000 digital camera (Gatan,
Warrendale, PA).
In Vitro Cleavage Assay
Different amounts of purified CatB from human liver (Sigma) were
preactivated with 4 mM cysteine at room temperature for 5 min in
assay buffer (pH 6.0 or 7.0 after adjustment) (Cathepsin B Activity
Assay Kit, EMD Biosciences). Then, 20 ng of fresh, protofibrillar, or
fibrillar Ab1-42 was added and incubated at 37C for 120 min. All
samples were run in parallel with and without the specific CatB in-
hibitor CA074. CatB-induced peptidase cleavage of Ab1-42 was de-
tected with mass spectrometry. Briefly, 5 ml of the reaction mixture
was applied to an NP-20 normal-phase chip (Ciphergen Biosystems,
Fremont, CA), and the spots were washed with water and air dried.
Twenty percent a-cyano-4-hydroxycinnamic acid in 50% acetoni-
trile, 0.5% trifluoroacetic acid (23 0.5 ml) was applied, and the chips
were allowed to dry. Samples were analyzed in a PBS IIC SELDI-TOF
mass spectrometer (Ciphergen) as an average of 160 shots for each
spot. The system was calibrated daily with All-in-One peptide stan-
dards (Ciphergen) and synthetic Ab1-42.
The products were also analyzed by western blotting on acid-urea
gels with an anti-Ab antibody (3D6) as described (DeMattos et al.,
2001; Esposito et al., 2004) or on a Tricine SDS-PAGE. Briefly,
10 ml of the reaction mixture was resolved on 16% tricine gels and
transferred to nitrocellulose membranes. Membranes were labeled
with 21F12 (1:2000, Elan Pharmaceuticals), an antibody specific
for Ab1-42, to detect low MW Ab1-42 oligomers. Since 21F12 was
unable to detect higher MW assemblies, 3D6 (1:2000, Elan) was
also used for immunoblotting. After incubation with an HRP-conju-
gated sheep anti-mouse IgG (1:2000; Amersham) secondary anti-
body, blots were developed with an ECL system (Perkin Elmer).
Quantification of CatB Activities and CatB mRNA
CatB activities in N2A cells or in hippocampus of hAPP mice and
their littermate controls were quantified with the Innozyme Cathep-
sin B Activity Assay Kit (EMD Biosciences), according to the manu-facturer’s instructions. Cells or hippocampi were lysed in lysis buffer
in the absence of proteinase inhibitors, preactivated with 4 mM cys-
teine, and incubated with the synthetic substrate Z-Arg-Arg AMC at
37C for 30 min. Released free AMC was determined fluorometrically
as above. The enzymatic activities inhibited by CA074 were defined
as CatB-specific activities. Protein concentrations were measured
with the BCA protein assay kit (Pierce) and used to normalize CatB
activities.
Expression of CatB was measured by quantitative RT-PCR. Total
RNA in N2A cells was isolated with Trizol reagent (Invitrogen). After
treatment with RNase-free DNase (Ambion) for 30 min at 37C, total
RNA (60 ng/ml) was reverse transcribed with random hexamers and
oligo d(T) primers. The expression of CatB relative to GAPDH was
determined with SYBR green dye chemistry and an ABI Prism
7700 sequence detector (Applied Biosystems, Foster City, CA), as
recommended by the manufacturer. Primer quality was verified by
dissociation curve analysis, the slopes of standard curves, and reac-
tions without RT. The following primers were used: mouse CatB (for-
ward, 50-TGGTTTCAGGTGGAGTCTACA-30; reverse, 50-TGCACTG
GAGAA GGAGATACT-30) and mouse GAPDH (forward, 50-GGG
AAGCCCATCACCATCTT-30; reverse, 50-GCCTTCTCCATGGTGGT
GAA-30).
Statistical Analysis
Statistical analyses were carried out with Graphpad Prism (San
Diego, CA). For quantification of calbindin and plaque load, experi-
menters were blinded to the genotypes of the mice. Differences
among multiple means were evaluated by ANOVA and the Tukey-
Kramer post hoc test. Differences between means were assessed
with the unpaired, two-tailed Student’s t test or the Mann-Whitney
U test. The null hypothesis was rejected at the 0.05 level.
Supplemental Data
The Supplemental Data include six supplemental figures and can be
found with this article online at http://www.neuron.org/cgi/content/
full/51/6/703/DC1/.
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